Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

287516

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. A conditional approval is given to therapies whose benefit of immediate availability outweighs the risk of having less comprehensive data. Still, regulators require additional data or testing before granting full approval. The decision of the Medicines and Healthcare products Regulatory Agency (MHRA) in the…

You must be logged in to read/download the full post.